Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC8A1 | P32418 | 13/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962091 | 0.91 | CDK4 (0.33) | RIPK1ALDH1A1HPGDHTT | |
| SCHEMBL4966412 | 0.91 | RIPK1 (0.40) | SLC8A1RIPK1 | |
| SCHEMBL4965201 | 0.90 | CDK4 (0.33) | SLC8A1RIPK1 | |
| SCHEMBL4663156 | 0.89 | RIPK1 (0.36) | SLC8A1RIPK1KDM4E | |
| SCHEMBL4662902 | 0.89 | RIPK1 (0.36) | SLC8A1RIPK1KDM4E | |
| SCHEMBL4664616 | 0.89 | RIPK1 (0.36) | SLC8A1RIPK1KDM4E | |
| SCHEMBL4756646 | 0.89 | SLC8A1 (0.33) | SLC8A1 | |
| SCHEMBL4962584 | 0.89 | CMA1 (0.36) | — | |
| SCHEMBL5138692 | 0.88 | SLC8A1 (0.33) | SLC8A1 | |
| SCHEMBL4962507 | 0.88 | SLC8A1 (0.36) | SLC8A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070159-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | claimed |
| US-20180085361-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-29 | — | — | US | claimed |
| US-8648080-B2 | Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility | RAQUALIA PHARMA INC. (JP) | 2014-02-11 | — | — | US | claimed |
| US-20120115820-A1 | ACID PUMP ANTAGONIST FOR THE TREATMENT OF DISEASES INVOLVED IN ABNORMAL GASTROINTESTINAL MOTILITY | RAQUALIA PHARMA INC. | 2012-05-10 | — | — | US | claimed |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | claimed |
| EP-1904454-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-02 | — | — | EP | claimed |
| WO-2006136552-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2006-12-28 | — | — | WO | claimed |
| US-20190070159-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | disclosed |
| US-20180085361-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-29 | — | — | US | disclosed |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| WO-2008095912-A2 | ENANTIOPURE PHARMACOLOGICALLY ACTIVE TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
| EP-1904454-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006136552-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070159-A1 | NOVEL PHARMACEUTICAL USES | ATP1A4, HRH2, ATP4A | SLC8A1 102/4885RIPK1 4125/4885KDM4E 796/4885 |
| US-20120115820-A1 | ACID PUMP ANTAGONIST FOR THE TREATMENT OF DISEASES INVOLVED IN ABNORMAL GASTROINTESTINAL MOTILITY | HRH2, SLC10A2, MLNR | SLC8A1 443/4885RIPK1 3871/4885KDM4E 4079/4885 |
| US-20180085361-A1 | NOVEL PHARMACEUTICAL USES | ATP1A4, HRH2, ATP4A | SLC8A1 102/4885RIPK1 4125/4885KDM4E 796/4885 |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | SLC8A1 4475/4885RIPK1 4483/4885KDM4E 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.